Adherence to Iron Chelation Therapy among Adults with Thalassemia: A Systematic Review

References

• Badawy SM, Thompson AA. Management challenges in thalassemia. In: Abutalib SA, Connors JM, Ragni MV, editors. Nonmalignant hematology, expert clinical review: questions and answer. Cham, Switzerland: Springer International Publishing AG; 2016. p. 39–51.
   Google Scholar
• Martin A, Thompson AA. Thalassemias. Pediatr Clin North Am. 2013;60(6):1383–1391.
   PubMed Web of Science ®Google Scholar
• Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood. 2018;132(17):1781–1791.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Cappellini MD. Β-Thalassemias. N Engl J Med. 2021;384(8):727–743.
   PubMed Web of Science ®Google Scholar
• Cao A, Galanello R. β-thalassemia. Genet Med. 2010;12(2):61–76.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733–3737.
   PubMed Web of Science ®Google Scholar
• Modell B, Letsky EA, Flynn DM, et al. Survival and desferrioxamine in thalassaemia major. Br Med J (Clin Res Ed). 1982;284(6322):1081–1084.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738–3744.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Beg U, Liem RI, et al. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Adv. 2021;5(2):570–583.
   PubMed Web of Science ®Google Scholar
• Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med. 2015;6:197–209.
   PubMed Web of Science ®Google Scholar
• Nazir HF, Alshizawi M. Neutropenia and life-threatening agranulocytosis among children with β-Thalassemia treated with oral iron chelators in a community with background of ethnic neutropenia. J Pediatr Hematol Oncol. 2020;42(8):e750–e755.
   PubMed Web of Science ®Google Scholar
• Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919–1929.
   PubMed Web of Science ®Google Scholar
• Wahidiyat PA, Yosia M, Sari TT. Comparison of deferiprone to deferasirox and deferoxamine to cardiac and hepatic T2* MRI in thalassemia patients: evidence-based case report. Acta Med Indones. 2018;50(2):168–176.
   PubMed Web of Science ®Google Scholar
• Hammond J, Thompson AA, Fogel MA, et al. Combination oral chelation in adult patients with transfusion-dependent thalassemia and high iron burden. J Pediatr Hematol Oncol. 2019;41(1):e47–e50.
   PubMed Web of Science ®Google Scholar
• Moon SJ, Lee WY, Hwang JS, et al. Accuracy of a screening tool for medication adherence: a systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. PLoS One. 2017;12(11):e0187139.
   PubMed Web of Science ®Google Scholar
• Nau DP, Steinke DT, Williams LK, et al. Adherence: adherence analysis using visual analog scale versus claims-based estimation. Ann Pharmacother. 2007;41(11):1792–1797.
   PubMed Web of Science ®Google Scholar
• Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015(217047):217047.
   PubMed Web of Science ®Google Scholar
• Loiselle K, Lee JL, Szulczewski L, et al. Systematic and meta-analytic review: medication adherence among pediatric patients with sickle cell disease. J Pediatr Psychol. 2016;41(4):406–418.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Elsedfy H, Soliman AT, et al. Clinical and biochemical data of adult thalassemia major patients (TM) with multiple endocrine complications (MEC) versus TM patients with normal endocrine functions: a long-term retrospective Study (40 years) in a tertiary care center in Italy. Mediterr J Hematol Infect Dis. 2016;8(1):e2016022.
   PubMed Web of Science ®Google Scholar
• Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008;6(Suppl 1):158–169.
   PubMedGoogle Scholar
• Rofail D, Abetz L, Viala M, et al. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument. Value Health. 2009;12(1):109–117.
   PubMed Web of Science ®Google Scholar
• Scalone L, Mantovani LG, Krol M, et al. Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 2008;24(7):1905–1917.
   PubMed Web of Science ®Google Scholar
• Trachtenberg F, Vichinsky E, Haines D, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86(5):433–436.
   PubMed Web of Science ®Google Scholar
• Akrawinthawong K, Chaowalit N, Chatuparisuth T, et al. Effectiveness of deferiprone in transfusion-independent β-thalassemia/HbE patients. Hematology. 2011;16(2):113–122.
   PubMed Web of Science ®Google Scholar
• Matsui D, Klein J, Hermann C, et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther. 1991;50(3):294–298.
   PubMed Web of Science ®Google Scholar
• Taher AT, Origa R, Perrotta S, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017;92(5):420–428.
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Abdin IA, El Safy UR, et al. Cardiac events and cardiac T2* in Egyptian children and young adults with β-thalassemia major taking deferoxamine. Hematol Oncol Stem Cell Ther. 2010;3(4):174–178.
   PubMedGoogle Scholar
• Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in β-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol. 1990;84(3):113–117.
   PubMed Web of Science ®Google Scholar
• Al-Refaie FN, Wickens DG, Wonke B, et al. Serum non-transferrin-bound iron in β-thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol. 1992;82(2):431–436.
   PubMed Web of Science ®Google Scholar
• Haghpanah S, Zarei T, Zahedi Z, et al. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent β-thalassemia. Hematology. 2014;19(4):187–191.
   PubMed Web of Science ®Google Scholar
• Berdoukas V, Bohane T, Tobias V, et al. Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy. Hematol J. 2005;5(7):572–578.
   PubMedGoogle Scholar
• Piga A, Longo F, Origa R, et al. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study. Br J Haematol. 2014;167(3):423–426.
   PubMed Web of Science ®Google Scholar
• Trachtenberg FL, Mednick L, Kwiatkowski JL, et al. Beliefs about chelation among thalassemia patients. Health Qual Life Outcomes. 2012;10(1):148.
   PubMed Web of Science ®Google Scholar
• Origa R, Danjou F, Cossa S, et al. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major. Br J Haematol. 2013;163(3):400–403.
   PubMed Web of Science ®Google Scholar
• Kidson-Gerber G, Lindeman R. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence? Br J Haematol. 2008;142(4):679–680.
   PubMed Web of Science ®Google Scholar
• Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145(2):245–254.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with kral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332(14):918–922.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL, Kim HY, Thompson AA, et al. Thalassemia clinical research network. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 2012;119(12):2746–2753.
   PubMed Web of Science ®Google Scholar
• Richardson ME, Matthews RN, Alison JF, et al. Prevention of heart disease by subcutaneous desferoxamine in patients with thalassaemia major. Aust N Z J Med. 1993;23(6):656–661.
   PubMedGoogle Scholar
• Efthimiadis GK, Hassapopoulou HP, Tsikaderis DD, et al. Survival in thalassaemia major patients. Circ J. 2006;70(8):1037–1042.
   PubMed Web of Science ®Google Scholar
• Almahmoud SY, Coifman KG, Ross GS, et al. Evidence for multidimensional resilience in adult patients with transfusion-dependent thalassemias: is it more common than we think? Transfus Med. 2016;26(3):186–194.
   PubMed Web of Science ®Google Scholar
• Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol. 1995;91(1):224–229.
   PubMed Web of Science ®Google Scholar
• Alymara V, Bourantas D, Chaidos A, et al. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematol J. 2004;5(6):475–479.
   PubMedGoogle Scholar
• Binding A, Ward R, Tomlinson G, et al. Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload. Eur J Haematol. 2019;103(2):80–87.
   PubMed Web of Science ®Google Scholar
• Ehlers KH, Giardina PJ, Lesser ML, et al. Prolonged survival in patients with β-thalassemia major treated with deferoxamine. J Pediatr. 1991;118(4 Pt 1):540–545.
   PubMed Web of Science ®Google Scholar
• Eshghi P. Complications of combined treatment with deferiprone and desferrioxamine in thalassemic patients. Iran J Med Sci. 2007;32(1):40–44.
   Google Scholar
• Goulas V, Kourakli-Symeonidis A, Camoutsis C. Comparative effects of three iron chelation therapies on the quality of life of greek patients with homozygous transfusion-dependent β-thalassemia. ISRN Hematol. 2012;2012:1–8.
   Google Scholar
• Hatzipantelis ES, Karasmanis K, Perifanis V, et al. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients. Hemoglobin. 2014;38(2):111–114.
   PubMed Web of Science ®Google Scholar
• Kidson-Gerber GL, Francis S, Lindeman R. Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic. Med J Aust. 2008;188(2):72–75.
   PubMed Web of Science ®Google Scholar
• Kosaryan M, Vahidshahi K, Karami H, et al. Survival of thalassemic patients referred to the Boo Ali Sina Teaching Hospital, Sari, Iran. Hemoglobin. 2007;31(4):453–462.
   PubMed Web of Science ®Google Scholar
• Matsui D, Hermann C, Klein J, et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol. 1994;34(9):944–949.
   PubMed Web of Science ®Google Scholar
• Mazza P, Amurri B, Lazzari G, et al. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. Haematologica. 1998;83(6):496–501.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Davis SA, Liu PP, et al. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine. Am J Hematol. 1992;41(1):61–63.
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Fischer R, Treadwell M, et al. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia. Ann N Y Acad Sci. 2005;1054:486–491.
   PubMed Web of Science ®Google Scholar
• Porter J, Bowden DK, Economou M, et al. Health-related quality of life, treatment satisfaction, adherence and persistence in β-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the EPIC clinical trial. Anemia. 2012;2012:297641.
   PubMedGoogle Scholar
• Rashid M, Karimi M. Compliance of deferoxamine injection in β-thalassaemia major patients in Iran. Transfus Med. 2012;22(2):104–107.
   PubMed Web of Science ®Google Scholar
• Taher A, Sheikh-Taha M, Koussa S, et al. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol. 2001;67(1):30–34.
   PubMed Web of Science ®Google Scholar
• Thuret I, Hacini M, Pégourié-Bandelier B, et al. Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results. Hematology. 2009;14(6):315–322.
   PubMed Web of Science ®Google Scholar
• Trachtenberg FL, Gerstenberger E, Xu Y, et al. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia. Qual Life Res. 2014;23(8):2277–2288.
   PubMed Web of Science ®Google Scholar
• Badawy SM. Technology and long-term health-related quality-of-life outcomes in children with nonmalignant disorders after reduced-intensity conditioning and stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1733.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA, Liem RI. Technology access and smartphone app preferences for medication adherence in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2016;63(5):848–852.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Barrera L, Sinno MG, et al. Text messaging and mobile phone apps as interventions to improve adherence in adolescents with chronic health conditions: a systematic review. JMIR Mhealth Uhealth. 2017;5(5):e66.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Kuhns LM. Texting and mobile phone app interventions for improving adherence to preventive behavior in adolescents: a systematic review. JMIR Mhealth Uhealth. 2017;5(4):e50.
   PubMedGoogle Scholar
• Badawy SM, Cronin RM, Hankins J, et al. Patient-centered eHealth interventions for children, adolescents, and adults with sickle cell disease: systematic review. J Med Internet Res. 2018;20(7):e10940.
   PubMed Web of Science ®Google Scholar
• Alberts NM, Badawy SM, Hodges J, et al. Development of the InCharge health mobile app to improve adherence to hydroxyurea in patients with sickle cell disease: user-centered design approach. JMIR Mhealth Uhealth. 2020;8(5):e14884.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Radovic A. Digital approaches to remote pediatric health care delivery during the COVID-19 pandemic: existing evidence and a call for further research. JMIR Pediatr Parent. 2020;3(1):e20049Jun 25
   PubMedGoogle Scholar
• Radovic A, Badawy SM. Technology use for adolescent health and wellness. Pediatrics. 2020;145(2):S186–S194.
   PubMed Web of Science ®Google Scholar
• Ramsey WA, Heidelberg RE, Gilbert AM, et al. eHealth and mHealth interventions in pediatric cancer: a systematic review of interventions across the cancer continuum. Psychooncology. 2020;29(1):17–37.
   PubMed Web of Science ®Google Scholar
• Heneghan MB, Hussain T, Barrera L, et al. Access to technology and preferences for an mHealth intervention to promote medication adherence in pediatric acute lymphoblastic leukemia: approach leveraging behavior change techniques. J Med Internet Res. 2021;23(2):e24893.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA, Kuhns LM. Medication adherence and technology-based interventions for adolescents with chronic health conditions: a few key considerations. JMIR Mhealth Uhealth. 2017;5(12):e202.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Morrone K, Thompson A, et al. Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia. Cochrane Database Syst Rev. 2019;6(6):CD012900.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Kuhns LM. Economic evaluation of text-messaging and smartphone-based interventions to improve medication adherence in adolescents with chronic health conditions: a systematic review. JMIR Mhealth Uhealth. 2016;4(4):e121.
   PubMed Web of Science ®Google Scholar
• Shah AC, Badawy SM. Telemedicine in pediatrics: systematic review of randomized controlled trials. JMIR Pediatr Parent. 2021;4(1):e22696.
   PubMedGoogle Scholar
• Shah AC, O’Dwyer LC, Badawy SM. Telemedicine in malignant and nonmalignant hematology: systematic review of pediatric and adult studies. JMIR Mhealth Uhealth. 2021;9(7):e29619.
   PubMed Web of Science ®Google Scholar
• Serlachius A, Badawy SM, Thabrew H. Psychosocial challenges and opportunities for youth with chronic health conditions during the COVID-19 pandemic. JMIR Pediatr Parent. 2020;3(2):e23057.
   PubMedGoogle Scholar